Basic Information
| LncRNA/CircRNA Name | GASL1 |
| Synonyms | NA |
| Region | GRCh38_8:102805517-102809971 |
| Ensemble | ENSG00000253669 |
| Refseq | NR_149020 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | gastric cancer |
| ICD-0-3 | C16 |
| Methods | qRT-PCR, Western blotting, in vitro knockdown etc. |
| Sample | human gatric carcinoma cell lines(SNU-16 and NCI-N87) |
| Expression Pattern | down-regulated |
| Function Description | The expression level of lncRNA GASL1 was significantly downregulated in gastric cancer tissues compared with adjacent normal tissues from patients with gastric carcinoma. In addition, serum levels of GASL1 were significantly decreased in patients with gastric carcinoma when compared with healthy controls. Serum GASL1 levels distinguished patients with gastric carcinoma from healthy controls, and low expression levels of GASL1 were associated with decreased postoperative survival time. GASL1 overexpression downregulated, while GASL1 knockdown upregulated ?-catenin expression. GASL1 overexpression inhibited, and GASL1 knockdown promoted gastric cancer cell proliferation. In addition, treatment with a Wnt agonist demonstrated no significant effect on GASL1 expression, however the inhibitory effect of GASL1 overexpression on cell proliferation was reduced following treatment with the Wnt agonist. |
| Pubmed ID | 30988785 |
| Year | 2019 |
| Title | LncRNA GASL1 Inhibits Tumor Growth in Gastric Carcinoma by Inactivating the Wnt/?-catenin Signaling Pathway |
External Links
| Links for GASL1 | GenBank HGNC NONCODE |
| Links for gastric cancer | OMIM COSMIC |